Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Righttothetopon Oct 15, 2020 9:26am
249 Views
Post# 31720191

Next Steps

Next StepsGiven that LABS has so far exceeded in executing on their plans for the future and that they actually pulled off a large pharma partnership (as I really did hope they would), here is what I see for the near future:

1) Secure a Stada-like deal for NA.  With obvious access to Bains, that might be easier now than one would think but a NA deal (primarily for the US) with a Tier 1 or 2 pharma would be wonderful

2) Get into the beverage market with a partnership with RedBull or Monster.  You have to believe that those 'X-Games' type companies are licking their chops to find a way to engage their market with a CBD/THC based offering and LABS, with the credibilty it now has globally and their GMP manufacturing platform, offers an excellent partner with plenty of scale and regionalized production.  Realize that this is a bit of a stretch and outside of the pharma business model, but this would be massive.  May as well scoop the others before they get there....cause they will, especially if the US opens up.

3) Keep working with research entities and get the brand out there.

4) Get the damn SP up so we can list in the US.  We have all this high horsepower on the Board, we need to use them!  And when I mean get the SP up, I don't mean a reverse split.

In the end, LABS is doing exactly what they said they would, and have been executing flawlessly.  They need to secure EU GMP quickly, to maintain the positive street cred and start moving to operational excellence to give the markets some peace.

While the price is bouncing around for a while, and while COVID didn't do us any favours, this company is an investment that will pay off large, sooner than one thinks.

IMO
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse